dc.contributor.author |
Lemmer, Yolandy
|
|
dc.contributor.author |
Semete, B
|
|
dc.contributor.author |
Booysen, L
|
|
dc.contributor.author |
Kalombo, Lonji
|
|
dc.contributor.author |
Katata, L
|
|
dc.contributor.author |
Jones, AT
|
|
dc.contributor.author |
Alexander, C
|
|
dc.contributor.author |
Khati, M
|
|
dc.contributor.author |
Swai, HS
|
|
dc.contributor.author |
Verschoor, JA
|
|
dc.date.accessioned |
2010-12-06T10:19:48Z |
|
dc.date.available |
2010-12-06T10:19:48Z |
|
dc.date.issued |
2010-06 |
|
dc.identifier.citation |
Lemmer, Y, Semete, B, Booysen, L et al. 2010. Targeted nanodrug delivery systems for the treatment of Tuberculosis. 3rd International CDTM symposium, Cardiff, UK, 26-28 June 2010, pp 1 |
en |
dc.identifier.uri |
http://hdl.handle.net/10204/4597
|
|
dc.description |
3rd International CDTM symposium, Cardiff, UK, 26-28 June 2010 |
en |
dc.description.abstract |
South Africa currently has the highest incidence of TB per 100000 (358 per 100000) people in the world. In 2007 alone 112000 people died of TB in South Africa, of which 94 000 (72%) were co-infected with HIV. Although TB treatments exist, poor patient treatment compliance and drug resistance pose a great challenge to TB treatment programs worldwide. To improve the current inadequate therapeutic management of TB, a polymeric anti-TB nanodrug delivery system for anti-TB drugs was developed that may enable entry, targeting, sustained release over long periods and uptake of the antibiotics in the cells, hence reducing the dose frequency and simultaneously improving patient compliance. |
en |
dc.language.iso |
en |
en |
dc.relation.ispartofseries |
POSTER |
en |
dc.subject |
Tuberculosis |
en |
dc.subject |
Nanodrug delivery systems |
en |
dc.subject |
TB treatments |
en |
dc.subject |
Anti-TB drugs |
en |
dc.subject |
Patient compliance |
en |
dc.title |
Targeted nanodrug delivery systems for the treatment of Tuberculosis |
en |
dc.type |
Conference Presentation |
en |
dc.identifier.apacitation |
Lemmer, Y., Semete, B., Booysen, L., Kalombo, L., Katata, L., Jones, A., ... Verschoor, J. (2010). Targeted nanodrug delivery systems for the treatment of Tuberculosis. http://hdl.handle.net/10204/4597 |
en_ZA |
dc.identifier.chicagocitation |
Lemmer, Yolandy, B Semete, L Booysen, Lonji Kalombo, L Katata, AT Jones, C Alexander, M Khati, HS Swai, and JA Verschoor. "Targeted nanodrug delivery systems for the treatment of Tuberculosis." (2010): http://hdl.handle.net/10204/4597 |
en_ZA |
dc.identifier.vancouvercitation |
Lemmer Y, Semete B, Booysen L, Kalombo L, Katata L, Jones A, et al, Targeted nanodrug delivery systems for the treatment of Tuberculosis; 2010. http://hdl.handle.net/10204/4597 . |
en_ZA |
dc.identifier.ris |
TY - Conference Presentation
AU - Lemmer, Yolandy
AU - Semete, B
AU - Booysen, L
AU - Kalombo, Lonji
AU - Katata, L
AU - Jones, AT
AU - Alexander, C
AU - Khati, M
AU - Swai, HS
AU - Verschoor, JA
AB - South Africa currently has the highest incidence of TB per 100000 (358 per 100000) people in the world. In 2007 alone 112000 people died of TB in South Africa, of which 94 000 (72%) were co-infected with HIV. Although TB treatments exist, poor patient treatment compliance and drug resistance pose a great challenge to TB treatment programs worldwide. To improve the current inadequate therapeutic management of TB, a polymeric anti-TB nanodrug delivery system for anti-TB drugs was developed that may enable entry, targeting, sustained release over long periods and uptake of the antibiotics in the cells, hence reducing the dose frequency and simultaneously improving patient compliance.
DA - 2010-06
DB - ResearchSpace
DP - CSIR
KW - Tuberculosis
KW - Nanodrug delivery systems
KW - TB treatments
KW - Anti-TB drugs
KW - Patient compliance
LK - https://researchspace.csir.co.za
PY - 2010
T1 - Targeted nanodrug delivery systems for the treatment of Tuberculosis
TI - Targeted nanodrug delivery systems for the treatment of Tuberculosis
UR - http://hdl.handle.net/10204/4597
ER -
|
en_ZA |